Clinical trials: Substance Withdrawal
Smoking, Sleep Disturbance
Racial Differences in Circadian and Sleep Mechanisms for Nicotine Dependence, Craving, and Withdrawal
The number one preventable cause of death in the world is tobacco use. Cigarette smoking in particular, costs an estimated $300 billion due to expenses related to medical care and lost productivity.
- Conditions
- Smoking, Sleep Disturbance, Nicotine Dependence
- Trial name
- NCT03968900
- Testing
- Sleep restriction condition, Sleep extension condition
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Substance Use Disorders
Substance Use Disorders and Tobacco Habits
In the department for substance use disorders at Uppsala University Hospital there are two wards. One that is locked, where the patients that are emitted can not go out to smoke and another ward where there is a possibility to go…
- Trial name
- NCT03118011
- Testing
- No smoking, Smoking
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Uppsala University
Smoking
Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal
Objectives: To evaluate neural correlates associated with emotional processing during nicotine withdrawal preferentially involving the amygdala and associated areas within the corticolimbic and mesolimbic circuitry.
- Trial name
- NCT00664404
- Testing
- Functional Magnetic Resonance Imaging (fMRI)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Neonatal Abstinence Syndrome, Substance Withdrawal, Neonatal
The Effect of Music Therapy on Newborns
The clinical study is evaluating the impact of music therapy on neonates, specifically infants with neonatal opioid withdrawal syndrome (NOWS).
- Trial name
- NCT03987165
- Testing
- Music Therapy
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tulane University
Opioid Use Disorder
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD).
- Trial name
- NCT06538558
- Testing
- Tezampanel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Proniras Corporation
Alcoholic Cirrhosis, Alcohol Abstinence
Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
This study examines the safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease who continue drinking.
- Conditions
- Alcoholic Cirrhosis, Alcohol Abstinence, Alcohol Withdrawal, Medication Toxicity
- Trial name
- BAWIC (NCT06840652)
- Testing
- Baclofen
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Corporacion Parc Tauli
Marijuana Dependence
Ph1 Marinol Interaction Study - Part 1 - 1
The purpose of this study is to examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety, pharmacokinetics (PK), and cardiovascular…
- Trial name
- NCT00438139
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Alcohol Withdrawal Syndrome
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
This study examine the efficacy of oral magnesium supplementation as an adjuvant therapy for decreasing intensity of alcohol withdrawal symptoms among inpatients requiring pharmacological treatment of their AWS.
- Trial name
- MAGMA (NCT03033823)
- Testing
- Magnesium
- Where
- 11 sites in France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Marijuana Dependence
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
The purpose of this study is to investigate the interaction between marijuana and two potential treatment medications: lofexidine and oral THC, with the direct goal of using this information to improve marijuana treatment outcome.
- Trial name
- NCT00373503
- Testing
- Lofexidine, dronabinol, Marijuana
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Neonatal Abstinence Syndrome
Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome
The purpose of this study is to examine the efficacy of a specially-constructed crib mattress that delivers gentle vibrations (stochastic vibrotactile stimulation) as a complementary, non-pharmacological intervention for treating…
- Trial name
- NCT02801331
- Testing
- Stochastic Vibrotactile Stimulation (SVS)
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Elisabeth B Salisbury
Cannabis Use Disorder
SCORE Emerging Adult Cannabis Use & Stress
The interface between cannabis use and stress is a particularly important focus for sex differences research in emerging adults.
- Trial name
- NCT05885542
- Testing
- Cannabidiol oral solution
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Medical University of South Carolina
Nicotine Dependence
Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals…
- Trial name
- NCT01048944
- Testing
- Bupropion SR, Nicotine Patch
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Southern Illinois University Carbondale
Marijuana Dependence
Ph1 Marinol Interaction Study - Part 2 - 1
This study will examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety, pharmacokinetics (PK), and cardiovascular effects of the…
- Trial name
- NCT00490269
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Nicotine Withdrawal, Marijuana Dependence
Medications Development for the Treatment of Cannabis Related Disorders
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
- Conditions
- Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence
- Trial name
- MTC (NCT01204723)
- Testing
- Active Aprepitant
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Smoking Cessation
Nicotine Patch Trial in Syrian Primary Care Settings
The study is a two-arm, parallel group, randomized, placebo-controlled, double blind trial, conducted at four primary health care centers in Aleppo, Syria, to test the efficacy of transdermal nicotine patch therapy vs.
- Trial name
- NCT01085032
- Testing
- Transdermal Nicotine
- Where
- Syria
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- University of Memphis
Opioid-Related Disorders, Opioid Withdrawal
Comparison of Three Opioid Detoxification Treatment Regimens
Despite an increased focus on treating opioid use disorder there are relatively few studies that compare the length of time required for detoxification with medications other than buprenorphine.
- Trial name
- NCT03678792
- Testing
- Buprenorphine/naloxone, Morphine, Tramadol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Opioid Use Disorder
Development of an Opioid Withdrawal Clinical Outcome Assessment
Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification.
- Trial name
- NCT07094672
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Opioid Use Disorder, Opioid Withdrawal
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use.
- Trial name
- NCT05712707
- Testing
- BXCL501 (180 micrograms), BXCL501 (240 micrograms), Lofexidine (Positive Control)
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- New York State Psychiatric Institute
Opioid Use Disorder, Opioid Withdrawal
Evaluating Buspirone to Treat Opioid Withdrawal
The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid…
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
- Trial name
- NCT05511909
- Testing
- Buspirone, Lofexidine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Maryland, Baltimore
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-CMA (NCT03911466)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- T. John Winhusen, PhD